Drugs / Bictegravir/emtricitabine/tenofovir alafenamide
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03259698 Background | Nov 2021 → Dec 2022 | HIV infectious disease | Unity Health Toronto | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bictegravir/emtricitabine/tenofovir alafenamide | “Participants will receive Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25mg (Biktarvy®) one tablet once daily as study drug to complete a 28 day course of PEP.” NCT03259698 ↗ |
| Route | Oral | “one tablet once daily” NCT03259698 ↗ |